Ambrx
  • About
  • Technology
  • Pipeline
  • Partnerships
  • Careers
  • News
  • Contact Us
  • English

News

  • Ambrx Appoints Gary Yeung as Chief Financial …

  • FDA Grants ARX788 Fast Track Designation for …

Press Releases

  • Ambrx Appoints Gary Yeung as Chief Financial …

  • FDA Grants ARX788 Fast Track Designation for …

A Phase 1 Study of ARX788, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Metastatic HER2-Positive Breast Cancer

by Mike Trout | Dec 11, 2019 | News, Publications | 0 comments

San Antonio Breast Cancer Symposium 2019 – ARX788 SABCS poster final-12.12

  • Privacy
  • Site Map
  • Terms of Use

© Copyright 2006-2021 Ambrx Inc. All rights reserved.